Seller record · Telehealth service

Next Vial

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S4, compounding disclosure: The page selling compounded PT-141 injections says PT-141 is FDA-approved for hypoactive sexual desire disorder in premenopausal women. The one approved bremelanotide is Vyleesi, an autoinjector; a compounded injection is not that product. The same page and the other product pages state that the compounded medication is not FDA-approved, which does not withdraw the claim. 1 more criterion also fails; see the table below.

At a glance

Next VialTelehealth service

6/8criteria passed

Price: Semaglutide $199 a month, or $99 a month on a 12-month plan; tirzepatide $249
Sells: compounded semaglutide injection, compounded tirzepatide injection, and 9 more
FDA letters: None on file

Visit Next Vial See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded semaglutide and tirzepatide on plans of one to twelve months, with sermorelin, NAD+ injections and nasal spray, PT-141, glutathione, B12, testosterone and men's health medication. It names one filling pharmacy in South Carolina, whose address it also prints for returns.

Operating entity Next Vial LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Next Vial's FAQ; Next Vial's terms
S2	Prescription gating	PASS	Next Vial's checkout site; Next Vial's FAQ
S3	Pharmacy identification	PASS	Next Vial's FAQ
S4	Compounding disclosure	FAIL	Next Vial's PT-141 product page; Next Vial's GLP-1 medications product page; the Drugs@FDA record
S5	Analytical documentation	FAIL	Next Vial's GLP-1 medications product page; Next Vial's FAQ; Next Vial's terms
S6	Business address	PASS	Next Vial's returns refund policy; Next Vial's contact page
S7	Price disclosure	PASS	Next Vial's GLP-1 medications product page; Next Vial's sermorelin product page; Next Vial's NAD+ injectable product page; Next Vial's PT-141 product page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSUS-based doctors review the answers to a set of medical questions and prescribe when suitable, and the answers name MD Integrations as the provider network.Source: Next Vial's FAQ; Next Vial's terms.

S2PASSThe start button on the GLP-1 page opens an intake whose first screen asks the buyer's age, and the answers say the medication is billed when it ships.Source: Next Vial's checkout site; Next Vial's FAQ.

S3PASSThe answers name Manifest Pharmacy at 1018 S. Batesville Road, Greer, SC 29650 as the pharmacy that may fill prescriptions.Source: Next Vial's FAQ.

S4FAILThe page selling compounded PT-141 injections says PT-141 is FDA-approved for hypoactive sexual desire disorder in premenopausal women. The one approved bremelanotide is Vyleesi, an autoinjector; a compounded injection is not that product. The same page and the other product pages state that the compounded medication is not FDA-approved, which does not withdraw the claim.Source: Next Vial's PT-141 product page; Next Vial's GLP-1 medications product page; the Drugs@FDA record.

S5FAILNo certificate of analysis or lot document is published on the product pages, the answers, the terms or the refund policy.Source: Next Vial's GLP-1 medications product page; Next Vial's FAQ; Next Vial's terms.

S6PASSNext Vial LLC care of Manifest Pharmacy at 1018 S. Batesville Road, Greer, SC 29650, printed as the returns address in the refund policy; it is also the address the answers give for the filling pharmacy. The contact page, the terms and the privacy policy print no other address.Source: Next Vial's returns refund policy; Next Vial's contact page.

S7PASSCompounded semaglutide at $199 a month, $169 a month on a 3-month plan billed $507, $149 on a 6-month plan billed $894 and $99 a month on a 12-month plan billed $1,188. Compounded tirzepatide at $249, $229, $199 and $149 a month on the same plans, billed $687, $1,194 and $1,788. The same page also prints doctor-led plans as low as $249.97 a month. Sermorelin at $199 a month down to $149 on 6 months, the NAD+ injection and nasal spray at $199 down to $129 a month on a 12-month plan billed $1,548, PT-141 at $199 or $149 a month on 3 months billed $447, glutathione from $149.99 and B12 from $139.Source: Next Vial's GLP-1 medications product page; Next Vial's sermorelin product page; Next Vial's NAD+ injectable product page; Next Vial's PT-141 product page.

S8PASSNo FDA warning letter names Next Vial or Next Vial LLC, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide injection, compounded tirzepatide injection, sermorelin, NAD+ injectable, NAD+ nasal spray, PT-141 (bremelanotide) injection, glutathione, B12 injectable, injectable and oral testosterone, sildenafil and tadalafil, hair loss and skincare treatments.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells sermorelin Who sells NAD+Who sells glutathione Who sells PT-141

Visit Next Vial

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.